PRADAXA Drug Profile


Which patents cover Pradaxa, and what generic alternatives are available?


Pradaxa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and eighty-seven patent family members in fifty-one countries.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.

Summary for PRADAXA 2018-01-23 09-52-09-433

Continue at:

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s